Faraday Pharmaceuticals
1616 Eastlake Avenue E
Suite 560
Seattle
Washington
98102
United States
Tel: 206-492-5310
Website: http://faradaypharma.com/
About Faraday Pharmaceuticals
Faraday Pharmaceuticals is a biopharmaceutical company pursuing the development of elemental reducing agents (ERAs). This pioneering approach focuses on the ability of specific reduced forms of elements to improve outcomes for patients.YEAR FOUNDED:
2014
LEADERSHIP:
CEO: Stephen A. Hill
CMO: Simon J. Tulloch
CFO and CBO: Brian Blackman
8 articles about Faraday Pharmaceuticals
-
Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio's pediatric methylmalonic acidemia study is back up and running and another look at Roche's TIGIT flop.
-
Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial InfarctionIocyte AMI-3 Trial
5/10/2022
Faraday Pharmaceuticals, Inc., today announced the enrollment of the first patient in its Iocyte AMI-3 study — a Phase 3 clinical trial assessing the efficacy and safety of FDY-5301 in reducing cardiovascular (CV) death and heart failure in anterior ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous intervention (PCI).
-
Faraday Pharmaceuticals Announces Publication of Results from its Phase 2 Study of FDY-5301 for the Treatment of Reperfusion Injury Following a STEMI Heart AttackTo be Published in the International Journal of Cardiology
12/27/2021
Faraday Pharmaceuticals, Inc. announced today the publication of results from its Phase 2 trial of FDY-5301 for the treatment of reperfusion injury following an ST-elevation myocardial infarction (STEMI) in the January 15, 2022 issue of the International Journal of Cardiology.
-
Clinical Catch-Up: October 11-15
10/18/2021
It was yet another busy week for clinical trial announcements. Take a look. -
Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study for ICU-Acquired Weakness
10/14/2021
Faraday Pharmaceuticals, Inc., a biopharmaceutical company dedicated to improving the quality of life for patients experiencing potentially life-changing critical illness by focusing on muscle health, announced the enrollment of its first patient in a Phase 2 study of FDY-5301.
-
Faraday Pharmaceuticals Announces Positive Top-Line Results from Phase 2 Trial of FDY-5301 for Treatment of Reperfusion Injury Following a STEMI Heart Attack
11/19/2019
Faraday Pharmaceuticals, a biopharmaceutical company focused on the development of small molecules for critical care medicine, today announced top-line results from its Phase 2 trial of FDY-5301 for the treatment of reperfusion injury following ST elevation myocardial infarction (STEMI)
-
Faraday Pharmaceuticals Announces Presentation of Clinical Data from Phase 2 Trial of FDY-5301 at the American Heart Association Scientific Sessions 2019
11/12/2019
Double-blind, placebo-controlled trial evaluating FDY-5301 for treatment of reperfusion injury following heart attack [12-November-2019] SEATTLE , Nov. 12, 2019 /PRNewswire/ -- Faraday Pharmaceuticals, a biopharmaceutical company focused on the development of elemental reducing agents for critical care medicine, today announced that top-line results from its Phase 2 t
-
Faraday Pharma Announces First-In-Human Trial Of FDY-5301
9/23/2016